KUALA LUMPUR, Malaysia, May 29, 2025 /PRNewswire/ -- The Health Industry Series - ASEAN (tHIS ASEAN 2025), a groundbreaking event aimed at integrating healthcare resources across Southeast Asia, is set to take place in Kuala Lumpur during June 9-11. Co-located with the APHM International Healthcare Conference & Exhibition 2025, hosted by the Association of Private Hospitals of Malaysia (APHM), the events together will bring together over 5,000 professionals from the region's medical and healthcare sectors.
Spanning over 5,000 square meters, tHIS ASEAN 2025 will feature more than 200 Chinese enterprises showcasing their latest healthcare innovations, products, and technologies. The event is expected to attract government officials, hospital procurement leaders, distributors, and agents from across ASEAN.
Malaysia's Strategic Role in ASEAN Healthcare
As one of ASEAN's most dynamic economies, Malaysia is rapidly increasing investment in healthcare infrastructure and services. The government's ongoing reforms and commitment to medical innovation have made it a strategic hub for global health collaboration. The launch of tHIS ASEAN reflects a deepening cooperation between China and ASEAN nations, fostering regional integration in healthcare technology, products, and services.
Diverse Exhibition Zones and Strategic Partnerships
Held in strategic partnership with APHM and its network of over 200 exhibitors, the event will benefit from shared audiences and enhanced industry reach. tHIS ASEAN will highlight five core sectors: medical devices, rehabilitation and elderly care, pharmaceuticals, hospital construction, and the medical component manufacturing and design. These zones will comprehensively showcase the depth and breadth of China's healthcare capabilities and their applications in Southeast Asian markets.
Thought-Leadership Forums and Insightful Dialogues
tHIS ASEAN 2025 will also host a series of high-level forums covering a wide range of topics, including:
- Innovative Technologies Shaping the Future of Medical Devices
- Pharmaceutical Innovation Products and Technologies Future Trends Conference
- ASEAN Rehabilitation and Elderly Care Industry Conference
- China-ASEAN Pharmaceutical Market Cooperation Forum
- Hospital of the Future: Innovation & Cooperation Conference
- Expanding into ASEAN: Regulations, Trends, and Cultural Considerations
Confirmed speakers include:
- Representative from Malaysia Device Authority (MDA) – "Medical Device Regulatory Pathways in Malaysia"
- Representative from Malaysia's NPRA – "Interpretation of Drug Import Registration Policies"
- Representative from Ministry of Health, Indonesia – "Medical Device Regulatory Pathways in Indonesia"
- CEO of Econ Healthcare group – "Current Development Situation of Rehabilitation and Elderly Care Industry in Singapore"
- Mindray – "Digital Transformation: Enhancing Clinical Outcomes with Intelligent Solutions"
- Representative from a TCM industry leader – "Millennial Heritage: Empowering Health Protection with New TCM Products"
To meet the diverse needs of attendees seeking targeted business opportunities, the event will feature a range of tailored services designed to enhance efficiency and foster meaningful connections. These include personalized one-on-one business matchmaking sessions, exclusive site visits to leading private hospitals, and curated networking activities — all designed to enhance efficiency, spark collaboration, and foster meaningful industry exchange. tHIS ASEAN aims to become the premier healthcare industry platform in Southeast Asia, driving forward healthcare innovation, service upgrades, and cross-border business cooperation. It marks a significant step toward a more integrated and innovative regional healthcare landscape.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
